Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$10.92 - $16.0 $116,057 - $170,048
10,628 New
10,628 $117,000
Q1 2023

May 15, 2023

SELL
$8.08 - $17.33 $408,040 - $875,164
-50,500 Reduced 5.33%
896,528 $14.9 Million
Q4 2022

Feb 14, 2023

BUY
$2.72 - $9.4 $109,888 - $379,760
40,400 Added 4.46%
947,028 $8.9 Million
Q3 2022

Nov 14, 2022

SELL
$2.55 - $3.89 $546,720 - $834,016
-214,400 Reduced 19.13%
906,628 $2.47 Million
Q2 2022

Aug 15, 2022

BUY
$2.11 - $3.15 $27,430 - $40,950
13,000 Added 1.17%
1,121,028 $3.24 Million
Q1 2022

May 16, 2022

BUY
$3.0 - $4.88 $688,800 - $1.12 Million
229,600 Added 26.14%
1,108,028 $3.32 Million
Q4 2021

Feb 14, 2022

SELL
$4.6 - $6.72 $277,840 - $405,888
-60,400 Reduced 6.43%
878,428 $4.04 Million
Q3 2021

Nov 15, 2021

SELL
$5.58 - $7.04 $253,332 - $319,616
-45,400 Reduced 4.61%
938,828 $5.9 Million
Q2 2021

Aug 16, 2021

SELL
$5.19 - $6.73 $217,980 - $282,660
-42,000 Reduced 4.09%
984,228 $5.9 Million
Q1 2021

May 17, 2021

BUY
$5.74 - $9.67 $3.23 Million - $5.44 Million
562,700 Added 121.4%
1,026,228 $6.49 Million
Q4 2020

Feb 16, 2021

BUY
$5.3 - $6.71 $2.02 Million - $2.56 Million
382,000 Added 468.55%
463,528 $2.61 Million
Q3 2020

Nov 16, 2020

BUY
$5.73 - $8.11 $240,820 - $340,847
42,028 Added 106.4%
81,528 $474,000
Q2 2020

Aug 14, 2020

BUY
$4.35 - $8.08 $171,825 - $319,160
39,500 New
39,500 $285,000
Q1 2019

May 15, 2019

SELL
$7.58 - $9.94 $101,572 - $133,196
-13,400 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$7.16 - $16.21 $134,608 - $304,748
-18,800 Reduced 58.39%
13,400 $103,000
Q3 2018

Nov 14, 2018

BUY
$9.7 - $19.65 $77,600 - $157,200
8,000 Added 33.06%
32,200 $561,000
Q2 2018

Aug 14, 2018

BUY
$3.88 - $12.74 $20,952 - $68,796
5,400 Added 28.72%
24,200 $230,000
Q1 2018

May 15, 2018

BUY
$4.11 - $6.93 $77,268 - $130,284
18,800 New
18,800 $82,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.